Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Proteomic Study of Urinary Stone Disease

2. september 2009 opdateret af: Lawson Health Research Institute

Urinary Proteomic Profiling Using ProteinChip SELDI-TOF-MS: A Potential Means of Identifying Protein Biomarkers of Urinary Stone Formers

Urinary protein levels are not routinely measured in stone patients while there is strong evidence that proteins play a role in the etiology of stones. The purpose of this study is to examine the urinary and serum proteins of stone formers compared to healthy subjects utilizing the high throughput method, Surface Enhanced Laser Desorption/Ionization (SELDI). We hypothesize that there is a unique set of proteins expressed in serum and urine in stone patients that can be detected by SELDI. Ultimately, this will better our understanding of stone disease and help develop new prevention strategies.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

Urinary stone disease affects 10% of the Canadian population during their lifetime and approximately half of these patients will have another episode within ten years. Currently, patients undergo metabolic testing (serum and 24 hour urine tests) to identify modifiable risk factors; however, no modifiable risk factors are identified in many patients, yet they continue to form stones. New techniques must be developed to identify stone patients at risk for future recurrences and ultimately to develop more specific prevention strategies.

Urinary protein levels are not routinely measured in stone patients while there is strong evidence that proteins play a role in the etiology of stones. The purpose of this study is to examine the urinary and serum proteins of stone formers compared to healthy subjects utilizing the high throughput method, Surface Enhanced Laser Desorption/Ionization (SELDI). We hypothesize that there is a unique set of proteins expressed in serum and urine in stone patients that can be detected by SELDI. Once a protein is identified as a biomarker, a specific assay similar to a quick and affordable dipstick test may be developed to identify those stone patients at risk of future stones. Ultimately, this will better our understanding of stone disease and help develop new prevention strategies.

Comparisons: protein profiles (serum/urine) of stone patients both during the presence of a stone and 6 weeks after they have passed it. comparison of stone profiles of stone patients with controls (non-forming stone patients).

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

20

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Canada
    • Ontario
      • London, Ontario, Canada, N6A 4V2
        • St. Joseph's Health Care London

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

This observational study will compare stone formers meeting the inclusion criteria with a cohort of age and sex matched non-stone formers as controls.

Beskrivelse

Inclusion Criteria:

  • Controls:

    • Ages 18 to 65 years of age
    • No history of stone disease and no radiographical evidence of stone (as demonstrated by negative ultrasound)
    • No family history of stones
    • Healthy and no autoimmune or systemic disease that may affect renal function (see exclusion criteria)

Stone patients

  • Ages 18 to 65 years of age
  • Solitary stone of any size, in any location along the urinary tract (except lower renal calyceal stones and bladder stones)
  • Radiology of any modality proving the existence of the stone (ultrasound, computed tomography, intravenous pyelogram, kidney-ureter-bladder x-ray)

Exclusion Criteria:

  • ALL:

    • Pregnant females
    • Male patients treated for with benign prostate hyperplasia (BPH) (ongoing medical treatment or surgical intervention within 6 months)
    • Positive urine culture
    • Any cancer (excluding superficial skin, brain)
    • Chronic Recurrent urinary infections (prostate, cystitis, vaginosis/vaginitis)
    • Gross hematuria
    • Autoimmune disease that may affect renal function (eg Systemic lupus erythematosus)
    • Renal dysfunction or its common causes:
    • Diabetes
    • Uncontrolled hypertension (with concurrent microalbuminuria) (diastolic BP > 90 mmHg)
    • glomerulonephritis
    • Renal transplant
    • Genetic stone disease (e.g. Cystine stones, xanthinuria)
    • Medullary sponge kidney, or other renal anomalies such as horseshoe kidney
    • GI disorders: Inflammatory bowel disease, short bowel
    • Hypercalcemic disorders (hyperparathyroidism, sarcoidosis, Paget's disease)
    • Renal tubular acidosis
    • Immunodeficient patients e.g. HIV (indinavir stones)
    • Unable to provide informed consent
    • Anyone in the opinion of the investigator who would be inappropriate

Controls :

  • In addition to criteria above.....
  • persistent thiazide use
  • Family history of stones (this will exclude any genetic factors since a positive family history increases the risk of urolithiasis)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Lawson Health Research Institute

Samarbejdspartnere

University of Western Ontario, Canada
The Physicians' Services Incorporated Foundation

Efterforskere

  • Ledende efterforsker: John D Denstedt, MD, FRCSC, The University of Western Ontario (Professor)

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. januar 2005

Primær færdiggørelse (Faktiske)

1. november 2008

Studieafslutning (Faktiske)

1. november 2008

Datoer for studieregistrering

Først indsendt

12. september 2005

Først indsendt, der opfyldte QC-kriterier

12. september 2005

Først opslået (Skøn)

20. september 2005

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

3. september 2009

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. september 2009

Sidst verificeret

1. september 2009

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • R-04-481
  • PSI 04-041

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Calculi

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in New Zealand

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner